Rebound vertebral and non-vertebral fractures during denosumab interruption in a postmenopausal woman.
Clin Endocrinol (Oxf). 2018 Sep 30;:
Authors: De Sousa SM, Jesudason D
Denosumab is a monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand (RANKL) with potent antiresorptive activity. In Australia, it is available alongside bisphosphonates as a first-line osteoporosis therapy on the Pharmaceutical Benefits Scheme (PBS). Denosumab is often preferred because of ease of administration, tolerability and safety/efficacy in patients with restricted renal function. Some dentists and clinicians may find denosumab attractive because of its reversibility, possibly allowing for dental procedures between injections or after a short interruption of therapy with a theoretically smaller risk of osteonecrosis of the jaw. This article is protected by copyright. All rights reserved.
PMID: 30269340 [PubMed – as supplied by publisher]